Hideki Iwahashi

Publication Activity (10 Years)

Years Active: 2017-2020
Publications (10 Years): 5

Top Topics

Long Non Coding Rna

Combination Therapy

Squamous Cell Carcinoma

Top Venues

Cancer chemotherapy and pharmacology

Medical oncology (Northwood, London, England)

Acta obstetricia et gynecologica Scandinavica

Pathology oncology research : POR

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroki Ishibashi, Morikazu Miyamoto, Hiroshi Shinmoto, Shigeyoshi Soga, Hiroko Matsuura, Soichiro Kakimoto, Hideki Iwahashi, Takahiro Sakamoto, Taira Hada, Rie Suzuki, Masashi Takano
The use of magnetic resonance imaging to predict placenta previa with placenta accreta spectrum. Acta obstetricia et gynecologica Scandinavica 99 (12) (2020)
Hiroaki Soyama, Morikazu Miyamoto, Hiroko Matsuura, Hideki Iwahashi, Soichiro Kakimoto, Hiroki Ishibashi, Takahiro Sakamoto, Taira Hada, Jin Suminokura, Masashi Takano
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine. Cancer chemotherapy and pharmacology 85 (5) (2020)
Soichiro Kakimoto, Morikazu Miyamoto, Takahiro Einama, Hiroko Matuura, Hideki Iwahashi, Hiroki Ishibashi, Takahiro Sakamoto, Taira Hada, Masashi Takano
Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma. Pathology oncology research : POR 26 (4) (2020)
Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matuura, Kento Kato, Takahiro Sakamoto, Mika Kuwahara, Hideki Iwahashi, Hiroki Ishibashi, Tomoyuki Yoshikawa, Kenichi Furuya
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer chemotherapy and pharmacology 81 (5) (2018)
Hiroaki Soyama, Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Mika Kuwahara, Kento Kato, Tomoyuki Yoshikawa, Hideki Iwahashi, Hitoshi Tsuda, Kenichi Furuya
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin. Medical oncology (Northwood, London, England) 34 (12) (2017)